UNIVERSITÄTSKLINIK FÜR HÄMATOLOGIE UND ONKOLOGIE

Publikationen

2022

  • Bethge WA, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner-Drouet EM, Wulf GG, Marks R, Penack O, Schnetzke U, Koenecke C, von Bonin M, Stelljes M, Glass B, Baldus CD, Vucinic V, Mougiakakos D, Topp MS, Fante MA, Schroers R, Bayir LM, Borchmann P, Buecklein V, Hanoun C, Thomas S, Beelen DW, Lengerke C, Kroeger N, Dreger P.
    GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany.
    Blood. 2022 Mar 22:blood.2021015209.
    Imp.-Fact.:23,629
  • Rejeski K, Perez A, Iacoboni G, Penack O, Bücklein V, Jentzsch L, Mougiakakos D, Johnson G, Arciola B, Carpio C, Blumenberg V, Hoster E, Bullinger L, Locke FL, von Bergwelt-Baildon M, Mackensen A, Bethge W, Barba P, Jain MD, Subklewe M.
    The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL.
    J Immunother Cancer. 2022 May;10(5):e004475.
    Imp.-Fact.:13,751
  • Koehler M, Hoppe S, Kropf S, Lux A, Bartsch R, Holzner B, Krauter J, Florschütz A, Jentsch-Ullrich K, Frommer J, Flechtner HH, Fischer T.
    Randomized Trial of a Supportive Psychotherapy for Parents of Adolescents and Young Adults With Hematologic Malignancies.
    J Natl Compr Canc Netw. 2022 Apr 11:1-15.
    Imp.-Fact.:11,908
  • Rücker FG, Du L, Luck TJ, Benner A, Krzykalla J, Gathmann I, Voso MT, Amadori S, Prior TW, Brandwein JM, Appelbaum FR, Medeiros BC, Tallman MS, Savoie L, Sierra J, Pallaud C, Sanz MA, Jansen JH, Niederwieser D, Fischer T, Ehninger G, Heuser M, Ganser A, Bullinger L, Larson RA, Bloomfield CD, Stone RM, Döhner H, Thiede C, Döhner K.
    Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.
    K.Leukemia. 2022 Jan;36(1):90-99.
    Imp.-Fact.:11,529
  • Schalk E, Biehl LM, Böll B.
    Jugular vein inserted central venous catheters (CVC) and the risk of CVC-related bloodstream infections in patients with hematological malignancies.
    Am J Hematol 2022; im Druck
    Imp.-Fact.:10
  • Böttcher M, Panagiotidis K, Bruns H, Stumpf M, Völkl S, Geyh S, Dietel B, Schroeder T, Mackensen A, Mougiakakos D.
    Bone marrow stroma cells promote induction of a chemoresistant and prognostic unfavorable S100A8/A9high AML cell subset.
    Blood Adv. 2022 Apr 7:bloodadvances.2021005938.
    Imp.-Fact.:6,779
  • Baldauf CK, Müller P, Haage TR, Adam-Frey S, Lokau J, Garbers C, Fischer T.
    Anti-IL-6 cytokine treatment has no impact on elevated hematocrit or splenomegaly in a polycythemia vera mouse model.
    Blood Adv. 2022 Jan 25;6(2):399-404.
    Imp.-Fact.:6,779
  • Bhuria V, Baldauf CK, Schraven B, Fischer T.
    Thromboinflammation in Myeloproliferative Neoplasms (MPN)-A Puzzle Still to Be Solved.
    Int J Mol Sci. 2022 Mar 16;23(6):3206.
    Imp.-Fact.:5,924
  • Schalk E, Hentrich M
    Real-World-Daten.
    Dtsch Arztebl Int 2022;119(8):134
    Imp.-Fact.:5,59
  • Gizem Özkan H, Thakor V, Xu HG, Bila G, Bilyy R, Bida D, Böttcher M, Mougiakakos D, Tietze R, Mokhir A.
    Anticancer Aminoferrocene Derivatives Inducing Production of Mitochondrial Reactive Oxygen Species.
    Chemistry. 2022 Apr 13:e202104420.
    Imp.-Fact.:5,236
  • Müller P, Baldauf CK, Haage TR, Charakopoulos E, Böttcher M, Bhuria V, Mougiakakos D, Schraven B, Fischer T.
    Genetic Knock-out of TNFR1 and TNFR2 in a JAK2-V617F Polycythemia Vera Mouse Model.
    Hemasphere. 2022 Apr 15;6(5):e717.

2021

  • Dudeck J, Kotrba J, Immler R, Hoffmann A, Voss M, Alexaki VI , Morton L, Jahn SR, Katsoulis-Dimitriou K, Winzer S, Kollias Georg, Fischer T, Nedospasov SA, Dunay IR, Chavakis T, Müller A J, Schraven B, Sperandio M, Dudeck A.
    Directional mast cell degranulation of tumor necrosis factor intoblood vessels primes neutrophil extravasation.
    Immunity, im Druck
    Imp.-Fact.:22,553
  • Osbelt L, Wende M, Almási E, Derksen E, Muthukumarasamy U, Lesker TR, Galvez EJC, Pils MC, Schalk E, Chhatwal P, Färber J, Neumann-Schaal M, Fischer T, Schlüter D, Strowig T.
    Klebsiella oxytoca causes colonization resistance against multidrug-resistant K. pneumoniae in the gut via cooperative carbohydrate competition.
    Cell Host Microbe 2021;29:1663-1679
    Imp.-Fact.:21
  • Surova A, Pech M, Gessner D, Mikusko M, Fischer T, Alter M, Wienke A.
    Low skeletal muscle mass is a predictor of treatment related toxicity in oncologic patients. A Meta-Analysis.
    Clinical Nutrition, im Druck
    Imp.-Fact.:7,324
  • Giesen N, Sprute R, Rüthrich M, Khodamoradi Y, Mellinghoff SC, Beutel G, Lueck C, Koldehoff M, Hentrich M, Sandherr M, von Bergwelt-Baildon M, Wolf HH, Hirsch HH, Wörmann B, Cornely OA, Köhler P, Schalk E, von Lilienfeld-Toal M; COVID-19 guideline panel of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
    2021 Update of the AGIHO guideline on evidence-based management of COVID-19 in cancer patients regarding diagnostics, viral shedding, vaccination and therapy.
    Eur J Cancer 2021;147:154-160
    Imp.-Fact.:7,3
  • Katsounas A, Schalk E.
    Infektionszahlen um ein Vielfaches höher.
    Dtsch Arztebl Int 2021; im Druck
    Imp.-Fact.:5,59
  • Schalk E, Hentrich M.
    Overweight or obesity are not risk factors for central venous catheter related bloodstream infections in patients with hematological malignancies.
    Infect Control Hosp Epidemiol 2021; im Druck
    Imp.-Fact.:3,3
  • Christian Straka, Hans Salwender, Stefan Knop, Martin Vogel, Jürgen Müller, Bernd Metzner, Christian Langer, Herbert Sayer, Wolfram Jung, Heinz A. Dürk, Florian Bassermann, Martin Gramatzki, Wolf Rösler, Hans-Heinrich Wolf, Wolfram Brugger, Monika Engelhardt, Thomas Fischer, Peter Liebisch, Hermann Einsele.
    Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma.
    Eur J Haematol. 2021, online ahead of print
    Imp.-Fact.:2,997
  • Böll B, Schalk E, Buchheidt D, Hasenkamp J, Kiehl M, Kiderlen TR, Kochanek M, Koldehoff M, Kostrewa P, Claßen AY, Mellinghoff SC, Metzner B, Penack O, Ruhnke M, Vehreschild MJGT, Weissinger F, Wolf HH, Karthaus M, Hentrich M.
    Central venous catheter-related infections in hematology and oncology: 2020 updated guidelines on diagnosis, management and prevention by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).
    Ann Hematol 2021;100(1):239-259
    Imp.-Fact.:2,9
  • Schalk E, Vehreschild MJGT, Biehl LM.
    Influence of different definitions of central venous catheter-related bloodstream infections on epidemiological parameters in cancer patients.
    Infect Control Hosp Epidemiol 2021;42(4):501-503
    Imp.-Fact.:2,86
  • Schmidt-Hieber M, Teschner D, Desole M, Link H, Maschmeyer G, Schalk E.
    Therapie von Infektionen bei Tumorpatienten.
    Schmoll HJ (Hrsg.), Kompendium Internistische Onkologie, 5. Auflage, Springer, 2021; im Druck

2020

  • Jayavelu AK, Schnöder TM, Perner F, Herzog C, Meiler A, Krishnamoorthy G, Huber N, Mohr J, Edelmann-Stephan B, Austin R, Brandt S, Palandri F, Schröder N, Isermann B, Edlich F, Sinha AU, Ungelenk M, Hübner CA, Zeiser R, Rahmig S, Waskow C, Coldham I, Ernst T, Hochhaus A, Jilg S, Jost PJ, Mullally A, Bullinger L, Mertens PR, Lane SW, Mann M, Heidel FH, Jayavelu AK, et al.
    Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms.
    Nature 2020 Dec;588(7836):157-163
    Imp.-Fact.:43,07
  • Rummelt C, Gorantla SP, Meggendorfer M, Charlet A, Endres C, Döhner K, Heidel FH, Fischer T, Haferlach T, Duyster J, von Bubnoff N.
    Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo.
    Leukemia. 2020 Nov 4.
    Imp.-Fact.:8,665
  • Giesen N, Sprute R, Rüthrich M, Khodamoradi Y, Mellinghoff SC, Beutel G, Lueck C, Koldehoff M, Hentrich M, Sandherr M, von Bergwelt-Baildon M, Wolf HH, Hirsch HH, Wörmann B, Cornely OA*, Köhler P*, Schalk E*, von Lilienfeld-Toal M*. (*Geteilte Letztautorenschaft)
    Evidence-based management of COVID-19 in cancer patients – Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
    Eur J Cancer 2020;140:86-104.
    Imp.-Fact.:7,3
  • Stemler J, Bruns C, Mellinghoff SC, Alakel N, Akan H, Ananda-Rajah M, Auberger J, Bojko P, Chandrasekar PH, Chayakulkeeree M, Cozzi JA, de Kort EA, Groll AH, Heath CH, Henze L, Hernandez Jimenez M, Kanj SS, Khanna N, Koldehoff M, Lee DG, Mager A, Marchesi F, Martino-Bufarull R, Nucci M, Oksi J, Pagano L, Philips B, Prattes J, Pyrpasopoulou A, Rabitsch W, Schalk E, Schmidt-Hieber M, Sidharthan N, Soler-Palacín P, Stern A, Weinbergerová B, El Zakhem A, Cornely OA, Koehler P.
    Baseline chest computed tomography as standard of care in high-risk hematology patients.
    J Fungi (Basel) 2020;6(1):36
    Imp.-Fact.:4,62
  • Jost F, Schalk E, Weber D, Doehner H, Fischer T, Sager S.
    Model-based optimal AML consolidation treatment.
    IEEE Trans Biomed Eng 2020;67(12):3296-3306
    Imp.-Fact.:4,424
  • Lilienthal P, Tetschke M, Schalk E, Fischer T, Sager S.
    Optimized and personalized phlebotomy schedules for patients suffering from polycythemia vera.
    Front Physiol 2020;11:328
    Imp.-Fact.:3,2
  • Zeremski V, Fischer T, Schalk E.
    Dose reduction and high-risk disease as risk factors for early death in primary CNS lymphoma.
    Leuk Lymphoma. 2020 Jan;61(1):240-242
    Imp.-Fact.:3,093
  • Salchow J, Mann J, Koch B, von Grundherr J, Jensen W, Elmers S, Straub LA, Vettorazzi E, Escherich G, Rutkowski S, Dwinger S, Bergelt C, Sokalska-Duhme M, Bielack S, Calaminus G, Baust K, Classen CF, Rössig C, Faber J, Faller H, Hilgendorf I, Gebauer J, Langer T, Metzler M, Schuster S, Niemeyer C, Puzik A, Reinhardt D,, Dirksen U,, Sander A, Köhler M, Habermann JK, Bokemeyer C, Stein A.
    Comprehensive assessments and related interventions to enhance the long-term outcomes of child, adolescent and young adult cancer survivors – presentation of the CARE for CAYA-Program study protocol and associated literature review
    BMC Cancer. 2020 Jan 6;20(1)
    Imp.-Fact.:2,933
  • Schalk E, Teschner D, Hentrich M, Böll B, Panse J, Schmidt-Hieber M, Vehreschild MJGT, Biehl LM.
    Central venous catheter-related bloodstream infections in patients with hematological malignancies: comparison of data from a clinical registry and a randomized controlled trial.
    Infect Control Hosp Epidemiol. 2020 Feb;41(2):254-256
    Imp.-Fact.:2,86
  • Ptok H , Schalk E , Hass P , Heinze C , Brunner T , Croner RS.
    Multimodale Therapie primärer, nicht metastasierter retroperitonealer Sarkome.
    Zentralbl Chir 2020;145(5):405-416
    Imp.-Fact.:0,7
  • Koehler M, Mann J, Richter D, Hilgendorf I
    Krebs bei Jugendlichen und jungen Erwachsenen. Status quo der interdisziplinären Versorgung in Deutschland
    Forum 2020 · 35:37–42

2019

  • Nimmagadda SC, Frey S, Müller P, Wolleschak D, Weinert S, Keller U, Edelmann B, Fischer T.
    SDF1a-induced chemotaxis of JAK2-V617F positive cells is dependent on Bruton's Tyrosine Kinase and its downstream targets PI3K/AKT, PLC gamma 1 and RhoA.
    Haematologica. 2019 Jul;104(7):e288-e292
    Imp.-Fact.:9,09
  • Hillert LK, Bettermann-Bethge K, Nimmagadda SC, Fischer T, Naumann M, Lavrik IN.
    Targeting RIPK1 in AML cells carrying FLT3-ITD.
    Int J Cancer. 2019 Mar 3. [Epub ahead of print]
    Imp.-Fact.:7,36
  • Lowinus T, Heidel FH, Bose T, Nimmagadda SC, Schnöder T, Cammann C, Schmitz I, Seifert U, Fischer T, Schraven B, Bommhardt U.
    Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of Kv1.3 potassium channels, AKT and ERK1/2 signaling.
    Cell Commun Signal. 2019 Jan 16;17(1):5.
    Imp.-Fact.:5,324
  • Salmanton-García J, Seidel D, Koehler P, Mellinghoff SC, Herbrecht R, Klimko N, Rácil Z, Falces-Romero I, Ingram P, Benítez-Peñuela MA, Rodríguez-Quintero J, Desoubeaux G, Barac A, Hoenigl M, Klyasova G, Puerta-Alcalde P, Cheng MP, Heinz WH, Iqba N, Krausen R, Ostermann H, Penack O, Schalk E, Sheppard DC, Willinger B, Wisplinghoff H, Vehreschild JJ, Cornely OA, Vehreschild MJGTZ, on behalf of The FungiScope® ECMM/ISHAM Working Group.
    Matched-paired analysis of patients treated for invasive mucormycosis - standard treatment vs. posaconazole new formulations (MoveOn).
    J Antimicrob Chemother. 2019 Nov 1;74(11):3315-3327
    Imp.-Fact.:5,113
  • Schalk E, Katsounas A.
    HIV/AIDS-related refractory Kaposi sarcoma causing severe leg lymphedema.
    Open Forum Infect Dis. 2019 Sep 18;6(10):ofz407.
    Imp.-Fact.:3,371
  • Schmidt-Hieber M, Teschner D, Maschmeyer G, Schalk E.
    Management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation.
    Expert Rev Anti-Infect Ther 2019;17(12):983-995
    Imp.-Fact.:3,141
  • Probst L, Schalk E, Liebregts T, Zeremski V, Tzalavras A, von Bergwelt-Baildon M, Hesse N, Prinz J, Vehreschild JJ, Shimabukuro-Vornhagen A, Eichenauer DA, Garcia Borrega J, Kochanek M, Böll B; Working Party on Intensive Care Medicine in Hematologic and Oncologic Patients (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO).
    Prognostic accuracy of SOFA, qSOFA and SIRS criteria in hematological cancer patients: a retrospective multicenter study.
    J Intensive Care 20197;7:41.
    Imp.-Fact.:3,1
  • Tölle D, Hentrich M, Pelzer BW, Kremer P, Einhell S, Schulz S, Böll B, Panse J, Schmidt-Hieber M, Teschner D, Schalk E.
    Impact of neutropenia on central venous catheter-related bloodstream infections in patients with hematological malignancies at the time of central venous catheter insertion: A matched-pair analysis.
    Infect Control Hosp Epidemiol 2019;40(10):1204-1206.
    Imp.-Fact.:3,084
  • Zeremski V, Jentsch-Ullrich K, Kahl C, Mohren M, Eberhardt J, Fischer T, Schalk E.
    Is bendamustine-rituximab a reasonable treatment in selected older patients with diffuse large B-cell lymphoma? Results from a multicenter, retrospective study.
    Ann Hematol 2019;98(12):2729-2737
    Imp.-Fact.:2,85
  • Kochanek M, Schalk E, von Bergwelt-Baildon M, Beutel G, Buchheidt D, Henze L, Hentrich M, Kiehl M, Liebregts T, von Lilienfeld-Toal M, Löhnert M, Mellinghoff S, Penack O, Piepel C, Böll B.
    Management of sepsis in neutropenic cancer patients: 2018 guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO).
    Ann Hematol 2019;98(5):1051-1069
    Imp.-Fact.:2,845
  • Jost F, Schalk E, Rinke K, Fischer T, Sager S.
    Mathematical models for cytarabine-derived myelosuppression in acute myeloid leukaemia.
    PLoS One 2019;14(7):e0204540.
    Imp.-Fact.:2,806
  • Schalk E, Zeremski V, Fischer T.
    Primary ecthyma gangraenosum due to central venous catheter-related bloodstream infection with Pseudomonas aeruginosa.
    Infection 2019;47(2):333-334
    Imp.-Fact.:2,773
  • Straka C, Knop S, Vogel M, Müller J, Kropff M, Metzner B, Langer C, Sayer H, Jung W, Dürk HA, Salwender H, Wandt H, Bassermann F, Gramatzki M, Rösler W, Wolf HH, Brugger W, Fischer T, Liebisch P, Engelhardt M, Einsele H.
    Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials.
    Eur J Haematol. 2019 Sep;103(3):255-267, Epub 2019 Jul 19.
    Imp.-Fact.:2,217
  • Schalk E, Fischer T, Wolleschak D.
    Splenic cyst after abdominal trauma?
    Dtsch Arztebl Int 2019;116:362

2018

  • Lipka DB, Lutsik P, Plass C.
    From Basic Knowledge to Effective Therapies
    Cancer Cell, Volume 34, Issue 6, 10 December 2018, Pages 982-995.e7
    Imp.-Fact.:22,844
  • Edelmann B, Gupta N, Schnöder T, Oelschlegel AM, Shahzad K, Goldschmidt J, Philipsen L, Weinert S, Ghosh A, Saalfeld FC , Nimmagadda SC, Müller P, Braun-Dullaeus RC, Mohr J, Wolleschak D, Kliche S, Amthauer H, Heidel F, Schraven B, Isermann B, Müller AJ, Fischer T.
    JAK2-V617F promotes venous thrombosis through ß1/ß2 integrin activation
    J Clin Invest. 2018;128(10):4359-4371
    Imp.-Fact.:13,25
  • Maifrede S, Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, Solecka M, Lian Z, Belyaeva EA, Nersesyan A, Machnicki MM, Toma M, Chatain N, Rydzanicz M, Zhao H, Jelinek J, Piwocka K, Sliwinski T, Stoklosa T, Ploski R, Fischer T, Sykes SM, Koschmieder S, Bullinger L, Valent P, Wasik M, Huang J, Skorski T.
    Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
    Blood. 2018 May 21. pii: blood-2018-02-834895.[Epub ahead of print]
    Imp.-Fact.:13,164
  • Mohr J, Dash BP, Schnöder T, Wolleschak D, Herzog C, Santamaria NT, Weinert S, Godavarthy S, Zanetti C, Naumann M, Hartleben B, Huber TB, Krause DS, Kähne T, Bullinger L, Heidel F
    The cell fate determinant Scribble is required for maintenance of hematopoietic stem cell function
    Leukemia, volume 32, 1211–1221 (2018)
    Imp.-Fact.:10,023
  • Nimmagadda SC, Frey S, Edelmann B, Hellmich C, Zaitseva L, König GM, Kostenis E, Bowles KM, Fischer T.
    Bruton's tyrosine kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia.
    Leukemia. 2018 Mar;32(3):846-849.
    Imp.-Fact.:10,023
  • Paschka P, Schlenk RF, Weber D, Benner A, Bullinger L, Heuser M, Gaidzik VI, Thol F, Agrawal M, Teleanu V, Lübbert M, Fiedler W, Radsak M, Krauter J, Horst HA, Greil R, Mayer K, Kündgen A, Martens U, Heil G, Salih HR, Hertenstein B, Schwänen C, Wulf G, Lange E, Pfreundschuh M, Ringhoffer M, Girschikofsky M, Heinicke T, Kraemer D, Göhring G, Ganser A, Döhner K, Döhner H.
    Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.
    Leukemia. 2018 Apr 17. [Epub ahead of print]
    Imp.-Fact.:10,023
  • Heinicke T, Labopin M, Schmid C, Polge E, Socié G, Blaise D, Mufti GJ, Huynh A, Brecht A, Ledoux MP, Cahn JY, Milpied N, Scheid C, Hicheri Y, Mohty M, Savani BN, Nagler A.
    Reduced Relapse Incidence with FLAMSA-RIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Biol Blood Marrow Transplant. 2018 Aug 6. [Epub ahead of print]
    Imp.-Fact.:4,484
  • Dash BP, Schnöder TM, Kathner C, Mohr J, Weinert S, Herzog C, Godavarthy PS, Zanetti C, Perner F, Braun-Dullaeus R, Hartleben B, Huber TB, Walz G, Naumann M, Ellis S, Vasioukhin V, Kähne T, Krause DS, Heidel FH.
    Diverging impact of cell fate determinants Scrib and Llgl1 on adhesion and migration of hematopoietic stem cells.
    J Cancer Res Clin Oncol. 2018 Aug 6. [Epub ahead of print]
    Imp.-Fact.:3,282
  • Marhäll A, Heidel F, Fischer T, Rönnstrand L.
    Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
    Ann Hematol. 2018 May;97(5):773-780.
    Imp.-Fact.:3,083
  • Kiehl MG, Beutel B, Böll B, Buchheidt D, Forkert R, Fuhrmann V, Knöbl P, Kochanek M, Kroschinsky F, La Rosée P, Liebregts T, Lück C, Olgemoeller U, Schalk E, Shimabukuro-Vornhagen A, Sperr WR, Staudinger T, von Bergwelt Baildon M, Wohlfarth P, Zeremski V, Schellongowski P
    Consensus statement for cancer patients requiring intensive care support.
    Ann Hematol 2018 Jul;97(7):1271-1282
    Imp.-Fact.:3,083
  • Schmidt-Hieber M, Bierwirth J, Buchheidt D, Cornely OA, Hentrich M, Maschmeyer G, Schalk E, Vehreschild JJ, Vehreschild MJGT for the AGIHO Working Group.
    Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
    Ann Hematol January 2018, Volume 97, Issue 1, pp 31–49
    Imp.-Fact.:3,083
  • Mellinghoff SC, Bassetti M, Dörfel D, Hagel S, Lehners N, Plis A, Schalk E, Vena A, Cornely OA
    Isavuconazole shortens the QTc interval
    2018 Apr;61(4):256-260. Epub 2018 Jan 3.
    Imp.-Fact.:2,252
  • Lilienthal P, Tetschke M, Pottgiesser T, Fischer T, Schalk E, Sager S.
    Mathematical Modeling of RBC count dynamics after blood loss.
    Processes 2018;6(9):157
    Imp.-Fact.:1,279
  • Schmidt-Hieber M, Teschner D, Schalk E.
    Febrile Neutropenie – Risikofaktoren, Prophylaxe und Algorithmen zur antimikrobiellen Therapie.
    Journal Onkologie 2018;5:25-33
  • Fischer T.
    Das internistische Jahr 2017 - die wichtigsten Fortschritte und Entwicklungen
    Ärzteblatt Sachsen-Anhalt. Bd. 29.2018, 4, S. 17-20;

 

Letzte Änderung: 20.06.2022 - Ansprechpartner:

Sie können eine Nachricht versenden an: Webmaster
Sicherheitsabfrage:
Captcha
 
Lösung: